None

Table: PCSK9 data comps

Piecing together PCSK9 PCSK9 data comps Phase II proof-of-concept data presented at last week's American Heart Association meeting in Los Angeles provide further evidence to support the safety and eff...

Cardiovascular endocrinology in 2012: PCSK9—an exciting target for reducing LDL-cholesterol levels

Systemic administration of anti-PCSK9 antibodies induces dramatic reductions in LDL-cholesterol levels, and the effect of this therapy on LDL-receptor activity seems to be additive to that of statin t...

Large LDL Drops on Top of Max Statin With Anti-PCSK9 Antibody

New data on the anti-PCSK9 antibody REGN727/SAR236553 show impressive reductions in LDL levels even when the agent is added on top of high-dose atorvastatin. Heartwire

PCSK9 In The Spotlight Ahead Of AHA Meeting

Publication of full Phase II results for Sanofi/Regeneron’s SRA236553 in the New England Journal of Medicine put the focus on the PCSK9 class days ahead of the annual AHA meeting, where Amgen and Pf...

The Medicines Co. Enters PCSK9 Race With Alnylam Deal

The Medicines Company and RNAi therapeutics company Alnylam have teamed up to develop a new drug targeting PCSK9 for the treatment of high cholesterol, but they are far behind the leaders in the pack...

Aegerion Upbeat On Juxtapid Launch, Stares Down PCSK9 Threat

Aegerion said the U.S. launch of Juxtapid in its initial HoFH population was going according to plan. Management spoke of a few upside surprises, including the high number of prescribing cardiologists...

[Articles] Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging,

The results suggest that PCSK9 inhibition could be a new model in lipid management. Inhibition of PCSK9 warrants assessment in phase 3 clinical trials.

Amgen and Pfizer's PCSK9 inhibitors step hopefully 'down the line'

Further Phase II data supporting a strong efficacy profile for Amgen’s and Pfizer’s PCSK9 inhibitors –AMG 145 and RN316 (PF-04950615) – generated excitement at the American H...

Effects of the Prosegment and pH on the Activity of PCSK9: EVIDENCE FOR ADDITIONAL PROCESSING EVENTS.

PCSK9, a target for the treatment of dyslipidemia, enhances the degradation of the LDL receptor (LDLR) in endosomes/lysosomes, up-regulating LDL-cholesterol levels. Whereas the targeting and degradati...

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.

ABSTRACT: BACKGROUND: During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) has been identified as a key regulator of serum LDL-cholesterol (LDL-C) levels. PCSK9 is secreted by...

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, binds to low-density lipoprotein (LDL) receptors, leading to their accelerated degradation and to increased LDL cholester...

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High-Dose Statin Therapy.

Proprotein convertase subtilisin kexin type 9 (PCSK9) is an enzyme that impairs low-density lipoprotein cholesterol (LDL-C) clearance from the plasma by promoting LDL receptor degradation. Patients wi...

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans.

Proprotein convertase, subtilisin/kexin type 9 (PCSK9), a key regulator of plasma LDL-cholesterol (c) and cardiovascular risk, is produced in liver and secreted into plasma where it binds hepatic LDL...